A New Model For A New Era Of Psychedelic Therapy

By Ben Comer, Chief Editor, Life Science Leader

By 2031, the Multidisciplinary Association for Psychedelic Studies, or MAPS, aims to have treated 1 million post-traumatic stress disorder (PTSD) patients with 3,4-methylenedioxymethamphetamine (MDMA), a psychoactive drug also known by the street names Ecstasy or Molly. Designated by the FDA as a Breakthrough Therapy in 2017 and currently undergoing Phase 3 trials in the U.S., Canada, and Israel, following the completion of an initial Phase 3 study in 2021, MDMA is the closest drug to FDA approval amid a rapidly expanding field of psychedelic medicines.